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Abstract
Insulin-producing cells derived from in vitro differentiation of stem cells and non-stem cells by using different 
factors can spare the need for genetic manipulation and provide a cure for diabetes. In this context, pancreatic 
progenitors differentiating to b-like cells garner increasing attention as b-cell replacement source. This kind 
of cell therapy has the potential to cure diabetes, but is still on its way of being clinically useful. The primary 
restriction for in vitro production of mature and functional b-cells is developing a physiologically relevant in 
vitro culture system which can mimic in vivo pathways of islet development. In order to achieve this target, 
different approaches have been attempted for the differentiation of pancreatic stem/progenitor cells to b-like 
cells. Here, we will review some of the state-of-the-art protocols for the differentiation of pancreatic progenitors 
and differentiated pancreatic cells into b-like cells with a focus on pancreatic duct cells. (Folia Histochemica et 
Cytobiologica 2019, Vol. 57, No. 3, 101–115)
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Abbreviations: 
3D — three-dimensional; Akt — protein kinase 1; 
ALDH1 — aldehyde dehydrogenase 1; ALK3 — 
activin-like kinase 3; ARIP — adult rat pancreatic 
ductal epithelial cell line; Arx — aristaless-related 
homeobox; Ascl1b — achaete-scute homolog 1b; 
BLCs — beta-like cells; BMP7 — bone morphoge-
netic protein 7; B-PMSCs — bovine pancreatic MSCs; 
BrdU — bromodeoxyuridine; CACs — centroacinar 
cells; CK19 — cytokeratin 19; CNF — ciliary neuro-
trophic factor; Dnmt1 — DNA methyltransferase 1; 
DT — diphtheria toxin; DTZ — dithizone; E12.5 
— embryonic day 12.5; eBCs — enriched b-clusters; 
EGF — epidermal growth factor; EGFP — enhanced 
green fluorescent protein; EGF-R — EGF receptor; 
EMT — epithelial-to-mesenchymal transition; Ex-4 
— exendin-4; FACS — fluorescence-activated cell 
sorting; FGF — fibroblast growth factor; Fstl3 — 
follistatin-like 3; GABA — gamma-aminobutyric acid; 
GFP — green fluorescent protein; GH — growth 
hormone; GLP-1 — glucagon-like peptide-1; HA 
— hyaluronic acid; HDAC — histone deacetylase; 
HDACi — histone deacetylase inhibitor; Hes-1 — 
Hairy/Enhancer of split-1; HGF — hepatocyte growth 
factor; hNEPT — human non-endocrine pancreatic 
tissue; Hnf6 — hepatocyte nuclear factor 6; ICCs 
— islet-like cell clusters; IDX-1 — islet duodenal 
homeobox-1; INS — insulin; IPCs — insulin-pro-
ducing cells; KGF — keratinocyte growth factor; 
KO — knockout; LIF — leukemia inhibiting factor; 
MafA/B — musculoaponeurotic fibrosarcoma onco-
gene A/B; MSCs — mesenchymal stem cells; NeuroD 
— neurogenic differentiation; Ngn3 — neurogenin 3; 
Nkx6.1 — NK6 homeobox 1; NPPCs — nestin-pos-
itive progenitor cells; NOD — non-obese diabetic; 
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NOD-SCID — non-obese diabetic-severe combined 
immunodeficiency; p16INK4a — tumor suppressor 
gene; PANC-1 — human pancreatic cancer cell line; 
PAX4 — paired box 4; PDEC — pancreatic duct 
epithelial cell; PDL — partial duct ligation; PDSCs 
— pancreatic duct stem cells; Pdx1 — pancreatic 
and duodenal homeobox 1; PI-MSCs — pancreatic 
islet-derived mesenchymal stem cells; PLGA — 
poly-lactic co-glycolic acid; PP — pancreatic poly-
peptide; PRL — prolactin; Px — pancreatectomy; 
RSPO1 — R-spondin-1; SCs — stem cells; siRNA 
— small interfering RNA; Sox9 — sex determining 
region Y box 9; STAT3 — signal transducer and 
activator of transcription 3; STZ — streptozotocin; 
Tcf2 — transcription factor 2; TF — transcription 
factor; T3 — tri-iodothyronine; TGF — transforming 
growth factor; YFP — yellow fluorescent protein.
Introduction
In recent decades, the occurrence of diabetes has 
increased globally, with over 425 million diabetic 
people living worldwide whose number is expected 
to be 629 million in 2045 [1]. Diabetes is a form of 
metabolic disorder characterized by dysfunction and 
loss of b-cell mass resulting in chronic hyperglycemia 
[2, 3]. Regarding the treatment of diabetes, exogenous 
insulin can only control blood glucose levels without 
amending the devastating consequences of diabetes. 
Islet transplantation also has potential and is a clin-
ical method for restoring normoglycemia, however, 
not without problems related to donor shortage 
and immune rejection for which long term immune 
suppression therapy is necessary [4]. Alternatively, 
a stem-cells-based b-cell replacement can resolve most 
disease-related problems of diabetic patients [5, 6].
The pancreas is composed of exocrine (acinar, 
centroacinar and ductal cells) and endocrine com-
partments (islet of Langerhans) [7, 8]. Regarding the 
regeneration, most of the adult tissues are composed 
of the differentiated cells making them dependent on 
stem cells for repair and regeneration [9]. However, 
some tissues like adult pancreas lack the existence 
of true stem cells, undifferentiated cells which are 
dedicated for providing an unlimited supply of freshly 
differentiated cells when these are lost, discarded, or 
needed in greater numbers, and rely on the unipo-
tent and/or multipotent facultative progenitors [10]. 
The facultative progenitors are differentiated cells 
responsible for particular functions, but they retain 
the ability to de-differentiate [11], proliferate and 
eventually redifferentiate towards another cell type 
[12] for repairing the tissue after injury [13].The plas-
ticity of differentiated pancreatic cells enables them 
to serve as a facultative progenitor in a tissue which 
lacks true stem cells [14, 15]. 
For the maintenance of b-cell mass, pancreat-
ic b-cells can duplicate themselves [16], but this 
proliferation is not enough to withhold the exces-
sive loss of b-cells in stress conditions. Recently, 
Domínguez-Bendala et al. reported that in the adult 
murine and human pancreas, when normal turnover 
of b-cells is required, b-cells are formed by the rep-
lication of existing b-cells or can also be formed by 
de-differentiated a-cells through an intermediate cell 
stage called ‘virgin b-cell’ [17]. The existence of ‘vir-
gin b-cell’, which serves as an intermediate stage for 
transdifferentiation of a-cells to b-cells, as a neogenic 
niche at the periphery of pancreatic islets of mice 
was confirmed by Meulen et al. through single-cell 
transcriptome analysis [18]. It has been suggested by 
studies in mice that during metabolic stress, b-cell 
de-differentiation, and then redifferentiation mech-
anisms regenerate the islets [19]. However, when 
the pancreas is damaged excessively then ductal cell 
progenitors’ regenerate islets [17]. The in vivo and in 
vitro studies have shown that pancreatic duct epithelial 
cells (PDECs), acinar cells, and centroacinar cells 
were the source for neogenesis of b-like cells (BLCs) 
[20–22]. The main characteristics of BLCs involve 
the ability to synthesize insulin; however, in most 
cases, the secretion of insulin stimulated by glucose 
and other agents is usually lower than in beta cells 
isolated from pancreatic islets. The in vitro studies 
on endocrine cells showed that replication of b-cells 
and transdifferentiation of a and d cells are possible 
sources of insulin producing b-like cells [23–25]. 
Additionally, the pancreatic islet-derived mesenchy-
mal stem cells also show some potential for in vitro 
development of b-like cells [26]. Added to their role 
as a b-cell replacement, in vitro derived BLCs can be 
used as a model to study diabetes pathology [27] and 
can also provide a consistent and uniform supply for 
the screening of pharmaceutical drugs for improving 
b-cell function and survival [28, 29]. However, for the 
success of these in vitro stem cell culture approaches 
imitation of in vivo islet milieu is required.
In this review, we summarized different protocols 
used for the differentiation of pancreatic progenitors 
to b-like cells. Furthermore, the available cell sources 
within the pancreas were also assessed for their po-
tential as the progenitors of b-cells.
Pancreatic exocrine cells  
as a source of b-cell/b-like cells
The exocrine part of the pancreas is more than 95% 
in rodents and the pancreas in humans also have 
more than 95% to 98% of the exocrine part [7, 30]. 
It includes the acinar cells — secreting digestive 
enzymes, centroacinar cells — secreting bicarbonate 
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ions and mucins, and pancreatic ducts — transferring 
these secretions to the duodenum [7]. All types of 
exocrine cells in the pancreas have been used in vitro 
for expansion into b-cells in different studies which 
will be discussed shortly.
Pancreatic ductal epithelial cell’s induction  
to b-cell/b-like cells
Lessons from classical animal models  
of b-cells regeneration
These models include mainly partial duct ligation 
(PDL) of the pancreatic duct, partial pancreatectomy 
(Px) and targeted b-cells damage by diphtheria toxin 
(DT) and streptozotocin (STZ). The PDL method 
used by Xu et al. [31] and Inada et al. [32] in adult 
mouse showed the presence of multipotent islet 
progenitors in ductal linings. Injury-induced by PDL 
caused the b-cell mass expansion. This b-cell mass 
expansion needed the activation of Nuerogenin3 
(Ngn3) gene expression which they believed to be 
the response for the inflammatory damage and loss 
of acinar cells due to injury [31, 32]. Inada et al. used 
carbonic anhydrase II-Cre-lineage tracing to explore 
the source of new b-cells [32]. Pancreatectomy model 
of 90% Px in adult rats by Li et al. [33] illustrates that 
mature epithelial duct cells can be dedifferentiated 
and become facultative progenitors which then dif-
ferentiate to both exocrine and endocrine cell types. 
During dedifferentiation resulting from pancreatec-
tomy, the duct cells lost Hnf6, a ductal differentiation 
marker [34, 35], and expressed Pdx1, Tcf2, and Sox9 
transcription factors, markers for embryonic pancreat-
ic epithelium [36–38]. These pancreatic epithelial cells 
acted as progenitors and differentiated to Ngn3+ cells. 
Differentiation and maturation of Ngn3+ progenitor 
cells led in the growing pancreas to the formation 
of MafA+, insulin+ cells [33]. In another murine mod-
el, the 60% pancreatectomy was used for finding the 
source of b-cell regeneration. The Sox9+ viral lineage 
tracing confirmed that in young, but not adult, mice 
and humans intra-islet pancreatic ducts are the source 
of b-cell regeneration [39]. In an adult mouse mod-
el, diphtheria toxin (DT) was used to ablate b-cells 
to show that epithelial cells within the pancreatic 
ducts contribute to the regeneration of endocrine and 
acinar cells. The results of lineage tracing in DT-in-
duced ablated b-cell mouse model showed that b-cells 
were regenerated from pancreatic ductal cells [40]. 
In another study, a model of streptozotocin-induced 
diabetic mice was used. The in vivo differentiation 
of oligopotent progenitors, which can differentiate 
into pancreatic ductal and endocrine cell types in-
cluding b-cells, was investigated and it was confirmed 
that after STZ-induced diabetes new b-cells were 
formed through differentiation of oligopotent pro-
genitors [41].
We have learned from these models that pancreas 
has the facultative multipotent progenitors, which are 
activated by a specific type of injury to the pancreas. 
Pancreatic ductal epithelial cells, particularly, are 
believed to be these multipotent progenitors which 
can give rise to either endocrine or exocrine cells 
depending on the severity of injury to the pancreas. 
However, the source of b-cell regeneration under 
physiological conditions is not confirmed hitherto.
In vitro b-cell expansion using pancreatic duct cells
Pancreatic duct epithelial cells can dedifferentiate 
when there is stress or injury to the pancreas and 
can re-differentiate to endocrine or exocrine cells 
depending on the severity of the injury. As described 
in classical models of differentiation, in the pancreas 
of adult mice, pancreatic duct epithelial cells (PDECs) 
can contribute to the regeneration of endocrine and 
exocrine cell types. The regenerative pathways and 
cell types that contribute to this process depend upon 
the severity of injury [40]. Therefore, most researchers 
have used pancreatic duct cells in their studies to find 
a potential cell therapy for diabetes. Here, we summa-
rize some protocols used in different studies for the 
differentiation of PDECs to islet cells or, particularly, 
insulin-secreting b-like cells.
Sox9+ ductal cells in the adult pancreas can be 
differentiated to b-cells in vitro, but this way of in 
vivo conversion remained controversial until the 
Zhang group reported first in vivo study to resolve 
this controversy [42]. Using lineage-tracing, Zhang 
et al. proved that genetically labeled Sox9+ adult 
rat pancreatic ductal cells could be induced to insu-
lin-secreting cells in vivo. They used hyperglycemia 
in combination with long-term, low-dose epidermal 
growth factor (EGF) infusion as synergistic stimulants 
for the induction of duct cells to insulin-secreting 
b-cells. This treatment resulted in normoglycemia 
in non-autoimmune diabetic mice [42]. Recently, 
Shaotang et al. found the multipotency of adult rat 
pancreatic ductal epithelial cells by inducing their 
differentiation into pancreatic islets, nerve cells, 
adipose cells, and osteoblasts [43]. The development 
of these target cells was made possible by respective 
culture protocols for directing the differentiation of 
PDECs [43]. Furthermore, Qadir et al. confirmed the 
existence of pancreatic progenitors in human exocrine 
pancreas and ductal epithelial cells were confirmed 
as pancreatic progenitors [8]. The human exocrine 
pancreas is a reservoir of multipotent cells expressing 
PDX1, an important transcription factor expressed 
by pancreatic endocrine progenitors [44] and ALK3, 
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and BMP receptor 1A which is associated with the 
regeneration of tissues [45], mostly found in major 
pancreatic ducts. Qadir et al. also showed that BMP7, 
which binds to ALK3 could stimulate pancreatic pro-
genitor cells proliferation [8].
Suarez-Pinzon et al. studied the effect of the 
combination of epidermal growth factor (EGF) and 
gastrin on inducing b-cells from pancreatic duct stem 
cells, both in human and mice [46]. Treatment with 
EGF and gastrin for two weeks in non-obese diabetic 
(NOD) mice with autoimmune diabetes (NOD-
SCID) resulted in normoglycemia as the b-cell mass 
was expanded from 15 to 47% of normal cell mass. 
Immunosuppressive therapy was not done as the com-
bination of EGF and gastrin reduced insulitis, show-
ing that this treatment could also stop autoimmune 
destruction of b-cells in NOD-SCID mice [46]. On 
the other hand, the glucagon-like peptide-1 analog, 
exendin-4, reversed hyperglycemia in diabetic NOD 
mice; though, this required synchronized immunosup-
pressive treatment with anti-lymphocyte serum [47]. 
In their next experiment, Suarez-Pinzon et al. showed 
that b-cell mass in adult human pancreatic islets was 
increased after combination therapy with EGF and 
gastrin both in vitro and in vivo, and this was as a result 
of the induction of b-cell neogenesis from pancreatic 
duct cells [48]. In both studies by Suarez-Pinzonet 
al., the mechanism which initiated the neogenesis of 
b-cells from pancreatic duct cells was not elucidated. 
However, the authors suggested that EGF caused an 
increase in the proliferation of CK19-positive duct 
cells while gastrin induced the expression of Pdx1 
and differentiation of Pdx1+ cells to insulin-positive 
b-like cells [48]. Likewise, the importance of EGF was 
reported that the perturbation of EGF-R-mediated 
signaling resulted in delayed b-cell development in 
EGF-R deficient (−/−) mice [49]. These studies 
showing regeneration of b-cell mass through the use of 
EGF and gastrin combination, not only reveal the role 
of these peptides in the differentiation of pancreatic 
progenitors to b-cells in the damaged pancreas but 
also support the concept that pancreatic ducts con-
tain the progenitor cells which can give rise to b-cells 
through epithelial-to-mesenchymal (EMT) cell tran-
sition [50]. The EMT requires some inducing stimuli, 
provision of which can cause in vivo regeneration of 
b-cells and also can cause the in vitro production of 
insulin-producing cells (IPCs) from pancreatic ductal 
epithelial cells. 
Hui et al. investigated the effect of glucagon-like 
peptide-1 (GLP-1) on inducing differentiation of 
pancreatic ductal epithelial cells into insulin-secreting 
cells [51]. To test the effect of GLP-1, rat (ARIP) 
and human (PANC-1) cell lines, both derived from 
the pancreatic ductal epithelium, were used. Using 
fluorescence-activated cell sorting (FACS) analysis, 
they showed that GLP-1 induced the differentiation 
of ARIP cells into insulin-synthesising cells, although 
it did not affected the phenotype of PANC-1 cells. 
The expression of Glut2, insulin, and glucokinase 
transcripts was increased respectively in ARIC cells 
after GLP-1 treatment. GLP-1 was found to be as-
sociated with cause of this differentiation of ARIP 
cells by inducing the expression of b-cell differenti-
ation marker, islet duodenal homeobox-1 (IDX-1). 
Albeit, the transfection of IDX-1 gene into PANC-1 
cells made them responsive to GLP-1 treatment. The 
effect of GLP-1 on differentiation was confirmed by 
using exendin-9, a GLP-1 receptor antagonist, which 
inhibited the expression of b-cell-specific genes from 
ARIP and PANC-1 cell line pancreatic epithelial cells 
[51]. In an attempt to improve the efficiency of GLP-1-
induced differentiation, Li et al. used sodium butyrate 
(C4H7NaO2), histone deacetylase inhibitor (HDACi), 
along with GLP-1 to differentiate the FACS-sorted 
nestin-EGFP-positive progenitor cells (NPPCs) of 
transgenic (nestin and EGFP) mice into insulin-pro-
ducing cells in vitro [52]. The treatment of purified 
nestin-EGFP-positive cells with a combination of 
sodium butyrate and HDACs resulted in increased 
levels of transcripts which encoded for pancreatic 
development factors and insulin. The population of 
insulin-secreting cells and volume, almost 65 ng when 
exposed to 25 mM glucose, of insulin secretion, both 
increased as a consequence. The addition of sodium 
butyrate resulted in de-condensation of chromatin 
whereas GLP-1 caused the increased expression of 
Pdx1 which by binding to the insulin gene promoted 
its transcription [52]. Additional evidence showed that 
HDACs treatment promoted Ngn3+ proendocrine 
lineage, obtained from rat embryo, differentiation 
to an increased pool of endocrine progenitors [53]. 
Treatment with trichostatin A and sodium butyrate, 
inhibitors of both class I and II HDACs enhanced 
the mass of the b-cell as assessed by quantification 
after immunohistological staining against insulin. 
These results also suggest that HDACs are one of the 
critical key factors in endo- and exocrine pancreatic 
differentiation [53].
Another study conducted by Chen et al. re-
ported the protocol to expand and differentiate 
rat PDECs into insulin-secreting islet-like cell 
clusters in a dynamic three-dimensional (3D) cell 
culture system [54]. They cultured cells for 14 days 
in serum-free culture media supplemented with 
nicotinamide, keratinocyte growth factor (KGF), 
and b-fibroblast growth factor (b-FGF) which re-
sulted in the formation of islet-like cell clusters. 
105Pancreatic b-cell replacement
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2019
10.5603/FHC.a2019.0013
www.fhc.viamedica.pl
These islet-like cellular clusters were positive for 
insulin detection in the extracellular fluid and cy-
toplasm after 14 days of differentiation. However, 
the obtained insulin-secreting cells were not as 
functional like human islet cells [54]. In a recent 
study, Tan et al. used fibroblast-coated Poly-lactic 
acid-co-glycolic acid (PLGA) diaphragm to form 
a biological membrane [20]. They cultured nestin-pos-
itive pancreatic stem cells isolated from Wistar rats 
and, using two-step induction method, pancreatic 
stem cells were induced into insulin-secreting cells. 
A two-step induction method was used: in the first 
step, pancreatic stem cells were cultured in a media 
supplemented with bFGF and nicotinamide. After 
the detection of islet-like cell mass in culture media, 
activin-A, b-catenin, and exendin-4 (Ex-4) were used 
as supplements. The results showed that the number 
of nuclei was higher in induced cells and cells in this 
group were aggregated. The amount of insulin secret-
ed upon stimulation was also significantly higher in 
the induced group as compared to the normal group 
but was not the same as of islet b-cells [20].
A summary of these and other factors used in 
different studies by various researchers for the dif-
ferentiation of pancreatic duct stem cells into insu-
lin-secreting BLCs is given in Table 1.
To sum up, till now we have learned that pan-
creatic ducts have the progenitors residing in their 
epithelium which can be differentiated in situ and ex 
vivo into BLCs by inducing their differentiation with 
a combination of different factors.
Acinar to b-cell neogenesis
Acinar cells are differentiated cells with a specialized 
function but have the plasticity to dedifferentiate to-
wards duct-like endocrine progenitor cell phenotype 
which further differentiates towards b-cells [13, 55]. 
In pathological terms, this is referred to as metaplasia 
which is important for tissue repair after the injury. 
Owing to the abundance of their number and their 
ability to give rise to b-cells, the acinar cells are also 
a reliable candidate for b-cell regeneration and re-
placement. The transformation capability of acinar 
cells is mainly influenced by the type and extent of the 
pancreatic injury as confirmed by the lineage-tracing 
studies [40, 56].
Baeyens et al. showed that administration of 
EGF and ciliary neurotrophic factor (CNF) to adult 
STZ-induced diabetic mice stimulated the conversion 
of acinar cells to BLCs. The neo-b-like cells were 
glucose-responsive and restored normoglycemia. 
This conversion was dependent on the expression of 
Ngn3 which in turn was mediated by the Stat3 sign-
aling [57]. The overexpression of three transcription 
factors (TFs), MafA, Pdx1, and Ngn3 in the acinar 
cells of transgenic mice in vivo resulted in acinar to 
b-cell reprogramming [58]. The overexpression of 
these three TFs caused the reprogramming-induced 
inflammation, which resulted in ductal cell metaplasia 
of acinar cells. The metaplasia of acinar to ductal cell 
phenotype resulted in the conversion of ductal cell 
phenotype to neo-b-cells. The neo-b-cells reversed 
diabetes in these mice and these results suggest that 
the expression of b-cell-specific transcription factors 
are the key to the transition of acinar cells to b-cells 
[58]. However, the viral vector system for the overex-
pression of TFs used in this study makes this approach 
less feasible for clinical application.
The in vitro culture of acinar cells, isolated from 
adult Wistar rats, in the presence of EGF and leukae-
mia inhibiting factor (LIF) inhibited the Notch1 sign-
aling resulting in neogenesis of b-like cells [59]. The 
inhibition of Notch1 signaling caused the dedifferen-
tiation of adult rat acinar cells to a state in which they 
expressed endocrine progenitor transcription factor, 
Ngn3, and afterwards differentiated with b-like cells. 
However, the newly formed b-cells were immature 
as compared to islet b-cells but they became mature 
phenotypically and resembled islet b-cells when trans-
planted at the ectopic site, under the kidney capsule 
of nude mice [59]. The presence of tri-iodothyronine 
(T3) receptors in murine embryonic pancreas laid the 
foundation for ex vivo culture of acinar cells in the 
presence of T3 to develop b-like cells [60]. Culturing 
of embryonic day 12.5 (E12.5) mouse embryonic 
pancreas tissue with T3 induced ductal phenotype at 
the expense of acinar tissue. Furthermore, T3 induced 
the endocrine fate in murine E12.5 pancreatic explant 
culture and also in the mouse acinar cell line 266-6. 
The T3-mediated conversion of acinar to b-cells was 
dependent upon the Akt signaling pathway and the 
T3-mediated effects were abrogated by Akt inhibitors 
[60]. These results confer that acinar cells can be con-
verted to b-like cells by the addition of T3 in culture 
media. Dagmar Klein et al. [21] showed that exposure 
of adult human non-endocrine pancreatic tissue 
(hNEPT) to BMP-7 resulted in the conversion of the 
Pdx1-positive ductal cells to insulin-expressing cells. 
BMP-7 exposure instigated the ectopic expression of 
endocrine transcription factors in the exocrine cells 
which triggered this conversion. The use of in vitro 
lineage tracing confirmed that insulin-secreting cells 
were derivatives of mature ductal cells [21].
Summarily, the transformation of acinar to b-cell/ 
/b-like cells is possible as evidenced in many studies 
reported. This transformation was not direct from 
acinar to b-cell, instead, it was mediated by Ngn3+ 
endocrine precursor cell phenotype. Thus, it may be 
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concluded that first acinar cells dedifferentiate back 
to progenitor phenotype and then redifferentiate to 
insulin-secreting cells.
Centroacinar cells as a source of b-cells
Centroacinar cells (CACs) are a type of the exocrine 
pancreas cell and are present at the centre of acini in 
Table 1. Factors which caused the differentiation of pancreatic duct epithelial cells to b-cell/b-like cells [20, 39, 42, 46, 48, 
51, 52, 54, 112–119]
Model and protocol used Main obtained results Reference
In vitro studies
Rat (ARIP*) and human (PANC-1) pancreatic 
ductal epithelial cells treated with GLP-1
ARIP cells were differentiated to insulin synthesizing cells while 
PANC-1 cells phenotype was not affected
51
Human islet cells containing endocrine and duct 
cells cultured for 4 weeks in media with EGF  
and gastrin
The number of CK19 positive duct cells expressing Pdx1, insulin, 
and C-peptide was significantly increased (+678%) with increased 
b-like cells (+118%). Thus, CK19 positive pancreatic ductal cells 
were a source of new b-cells
48
FACS-sorted PDECs from adult mouse cultured 
with bFGF
bFGF caused the differentiation of these cells to insulin-secreting 
cells
112
Murine FACS-sorted NPPCs exposed to GLP-1  
and sodium butyrate
The NPPCs were differentiated to insulin-producing cells 52
Culture of human pancreatic duct-rich populations 
with Ex-4, nicotinamide, KGF, Pdx-1 and NeuroD 
proteins
After two weeks of culture, human pancreatic progenitors were 
differentiated to insulin-producing cells
113
Pancreatic ductal fragments from mouse pancreas 
grown in RSPO1-based 3D cultures
The fragments developed to organoids able to differentiate into 
ductal as well as endocrine cells upon transplantation under kid-
ney capsule of immunodeficient mice
114
Progenitors from human and mouse embryonic  
pancreas stimulated by the Wnt agonist RSPO1, 
FGF10 and/or EGF in 3D cultures
Pancreatic progenitors were expanded to duct-like structures in 
the presence of EGF and were differentiated to cyst-like structures 
containing insulin, glucagon, and somatostatin-positive cells in the 
absence but not presence of EGF 
115
Rat PDSCs were cultured in a 3D cell culture system 
in media supplemented with nicotinamide, FGF, 
and KGF 
Rat PDSCs were differentiated to islet-like cell clusters which 
expressed insulin as detected by DTZ staining 
54
Adult mouse pancreatic progenitor-like cells were 
cultured in media supplemented with insulin,  
transferrin, selenium, glucose, and nicotinamide
After two weeks of culture small dense cell clusters were formed 
and insulin presence in these clusters was confirmed by DTZ 
staining
116
Rat NPPCs cultured in PLGA membranes in media 
supplemented with bFGF, nicotinamide, activin-A, 
b-catenin, and exendin-4 
Nestin-positive cells were differentiated mainly to insulin-secreting 




Human fetal pancreatic cells were transplanted  
to rats treated with KGF
The ductal cells proliferated and differentiated to b-cells resulting 
in increased b-cell mass 
117
NOD diabetic mice treated with EGF and gastrin After 2 weeks of treatment, normoglycemia was achieved and  
b-cell mass was expanded from 15% to 47% of normal cell mass  
as a result of neogenesis from pancreatic ductal networks
46
The human betacellulin-adenoviral vector was  
retrogradely injected to mice pancreatic duct 
The betacellulin gene transduction resulted in the formation of 
insulin-positive cells in the duct linings or associated islet-like cell 
clusters
118
STZ-diabetic rats were treated with GLP-1/ 
/exendin-4 
The number of small cell clusters in pancreatic ducts was increased 
which improved glucose tolerance in diabetic rats
119
The partly pancreatectomized transgenic mice  
overexpressing TGF-b used to find the source  
of b-cells
Intraislet pancreatic ductal networks were present in transgenic 
but not in wild type mice and lineage tracing confirmed that  
neo-b-cells were derivatives of duct cells
39
In non-autoimmune diabetic C57BL/6 mice hyper-
glycemia was induced by alloxan and mice were 
treated for 56 days with low dose EGF and gastrin
Lineage tracing showed that Sox9+ cells differentiated into insu-
lin-producing b-cells which normalized blood glucose levels
42
*The abbreviations are explained at the beginning of the paper
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juxtaposition to the terminal pancreatic ducts. CACs 
have a unique cell morphology and express the endo-
crine differentiation marker Sox9 [61–64]. Beer et al. 
reported that centroacinar cells (CACs) are a type of 
ductal pancreatic cell which possesses the progenitor 
properties and replaces b-cells in zebrafish [65].
The centroacinar cells in zebrafish led to the 
secondary islet formation after inhibition of Notch 
signaling [66]. The Nkx6.1-transgenic zebrafish 
showed fluorescent markers for endocrine pro-
genitor cell phenotype under the Notch-inhibition. 
The Notch-responsive cells were centroacinar cells, 
which showed a pancreatic endocrine progenitor 
phenotype and led to the regeneration of endocrine 
cells after Notch-inhibition [66]. In order to further 
assess the ability of centroacinar cells for endocrine 
pancreas regeneration in adult zebrafish, Delaspre 
et al. established the transcriptome of adult CACs. 
Then, through the use of gene ontology and in situ 
hybridization, they found that CACs were enriched in 
pancreatic progenitor markers. Moreover, new b-cells 
arose from CACs after b-cell ablation or partial pan-
createctomy as confirmed by the lineage tracing [22]. 
Another group also used the b-cell ablation model of 
zebrafish to show the progenitor properties of CACs. 
Ghaye et al. [67] developed the transgenic lines of 
Nkx6.1 and Ascl1b-positive cells expressing GFP. 
In the near complete b-cell ablation model of adult 
zebrafish, the Nkx6.1 cells were traced as progenitors 
of pancreatic tissue while Ascl1b-positive cells only 
gave rise to endocrine cells. These Nkx6.1 cells were 
present at the end to a ductal tree and were responsive 
to Notch signaling showing their centroacinar pheno-
type [67]. The findings of both of these studies suggest 
that adult CACs are similar to larval CACs and retain 
the ability for b-cell neogenesis. Thus, it is safe to say 
that CACs are the progenitors of endocrine cells, 
especially b-cells in larval as well as adult zebrafish.
For the probing of the progenitor capabilities of 
centroacinar cells in mammals Rovira et al. used the 
mouse as a model animal in their study [68]. They 
found that centroacinar and terminal ductal cells 
showed high levels of ALDH1 enzymatic activity 
which was used for FACS-based isolation of these 
cells. The transcription analysis of FACS-isolated cells 
revealed that they were not the differentiated cells but 
rather were enriched for markers associated with pan-
creatic endocrine progenitor population. Moreover, 
the culturing of CACs in suspension culture resulted 
in pancreatosphere formation which displayed the 
pancreatic endocrine and exocrine cell differentia-
tion capacity along with glucose-responsive insulin 
secretion. For pancreatosphere formation assays 
on CACs, cells were grown for 5–7 days in cultures 
enriched with EGF, FGF-2, B-27 cell culture supple-
ment, b-mercaptoethanol, nonessential amino acid, 
and LIF. Furthermore, the CACs and terminal ductal 
cells also showed intense expansion under chronic 
epithelial injury conditions [68]. These findings sup-
port the reported zebrafish studies and suggest that 
CACs cells are certainly adept of progenitor’s task to 
provide the upkeep of tissue homeostasis in the adult 
mouse pancreas.
In summary, so far, we have well understood that 
centroacinar cells are a type of progenitor cells in 
the pancreas with the ability of pancreatic exocrine 
and endocrine tissue regeneration according to the 
conditions. The findings of the studies mentioned 
above also support the b-cell neogenesis pathway for 
the regeneration of b-cell mass. These CACs cells can 
also be sorted in vitro for the expansion of islets or 
only b-cells to provide a source of b-cells replacement.
Figure 1 shows different factors used for in vitro 
differentiation of pancreatic ductal, acinar and cen-
troacinar cells to b-cell.
Endocrine cells giving rise to b-cells
The endocrine pancreas has various endocrine cell 
types secreting different hormones which are a-cells 
(glucagon), b-cells (insulin), d-cells (somatostatin), 
e-cells (ghrelin), and PP cells (pancreatic polypep-
tide) [7]. These hormone-secreting cells are found in 
condensed structures in the pancreas called islet of 




GLP-1, Exendin-4, EGF, bFGF, KGF, BMP-7
Nicotinamide, Sodium butyrate, Gastrin, Noggin,
Betacellulin, Forskolin, Dexamethasone, Activin A
EGF, CNF, LIF, T3, BMP-7
EGF, FGF, B27, b-mercaptoethanol
C Centroacinar cell
Figure 1. Some of the factors used for in vitro differentiation 
of pancreatic ductal (A), acinar (B) and centroacinar cells (C). 
The ductal and acinar cells do not directly transit to b-cell 
phenotype but instead first attain a progenitor stage and then 
redifferentiate to insulin-secreting cells. 
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Langerhans. Islet b-cells sense the glucose-in-blood 
concentration, synthesize and secrete insulin into 
blood circulation which is responsible for regulating 
glucose metabolism in the body [69]. The pancreatic 
islet is likely the dwelling to search for cellular sources 
of new b-cells because of the common developmental 
lineage between the different endocrine cells in the 
islet of Langerhans [70]. The possibilities of islet cells 
as progenitors will be discussed in this section. 
Potential of b-cell replication  
for its replenishing 
The primary mechanism for expansion of b-cell mass 
during the neonatal period of growth is the prolifer-
ation of existing b-cells [71]. Lineage tracing studies 
confirmed that the replication of preexisting b-cells 
is the main mechanism accountable for normal b-cell 
turnover in adult mice [16, 72] and also for regener-
ation of b-cell mass following b-cell ablation [73, 74]. 
So, in rodents, the major source for expansion of b-cell 
mass is the replication of existing b-cells [75]. Though 
the increase in b-cell mass of neonates occurs by repli-
cation of preexisting b-cell, this mechanism disappears 
after 2 years in humans [71, 76]. Under the physio-
logical conditions in adult humans, the regeneration 
of b-cells is rare, and so it is not confirmed hitherto 
from where comes the b-cells in normal conditions 
[7, 76]. However, the increased regenerative ability 
of b-cells in conditions of pregnancy [77] and obesity 
[78] gives us a clue about the replication of existing 
insulin-producing cells. Nonetheless, replication of 
existing b-cells and their in vitro expansion ability is 
a well-studied mechanism for restoring b-cell mass of 
diabetics [10, 79].
Dhawan et al. [23] reported that the likely reason 
for the decreased regenerative capacity of adult b-cells 
was an accumulation of p16INK4a which caused inhi-
bition of the cell cycle ending up in the limited regen-
erative capacity of adult endocrine cells. Additionally, 
they found that TGF-b signaling maintained the 
p16INK4a through Smad3 which joined in with trith-
orax to maintain and activate the p16INK4a levels to 
prevent the replication of b-cells. Thus, the inhibition 
of TGF-b signaling with different chemical inhibitors 
resulted in the repression of p16INK4a locus ending 
up in increased replication of b-cells in adult mice [23]. 
Recently, Puri et al. studied the role of c-Myc in b-cell 
replication [80]. They used c-Myc transgenic mice and 
INS-1 cells with c-Myc overexpression (siRNA) which 
were cultured with L-glutamine, sodium pyruvate 
and 2-mercaptoethanol. They showed that increased 
expression of c-Myc resulted in increased prolifera-
tion of b-cells but the cells produced were immature. 
The transcriptome analysis validated the immaturity 
of new b-cells as the proliferating cellular transcripts 
were increased and transcripts of the mature b-cells 
phenotype were decreased which resembled develop-
ment of islets [80]. Moreover, the genetic deletion of 
c-Myc resulted in a ~50% decline in the proliferative 
cell pool during postnatal expansion, which showed 
the importance of this protein during the replication 
of b-cells. The authors concluded that the adult b-cells 
retain a balance between functional and proliferative 
properties as the proliferation of b-cells leads to func-
tional immaturity [80].
Nielsen et al. reviewed the possible factors used for 
enhancement of b-cell replication in in vivo culture. 
Cytokines such as GLP-1, growth hormone (GH) 
and prolactin (PRL) were proposed as the tangible 
factors for the uplifting of in vitro b-cell replication. 
These factors worked best when the cells were dedif-
ferentiated and entered the proliferative phase [81]. 
In vitro expansion of b-cells using adult human islets 
was successfully attempted by Ouziel-Yahalo et al. 
[82]. The culturing conditions included activin A, 
betacellulin, and exendin 4 as differentiation-inducing 
factors. After seven days of culture, the number of 
b-cells was doubled as measured by BrdU labeling. 
The dedifferentiation of b-cells resulted in their 
increased size and redifferentiation to b-cell pheno-
type, especially in betacellulin supplemented media. 
However, the functionality of replicated b-cells was 
not high compared to the primary islet b-cells [82].
In summary, these studies suggest that b-cell rep-
lication is a possible mechanism and it involves the 
dedifferentiation of mature b-cells to cells with less 
mature phenotype which further proliferate to form 
new b-cells.
a- to b-cell transdifferentiation
Mature islet cell’s plasticity has remained a puzzle 
until lineage tracing models in mouse [83] and zebraf-
ish [84] confirmed the transdifferentiation ability of 
a-cells by the transition to b-cells given the conditions 
of severe b-cell loss [83, 84]. As we already know, adult 
b-cells have a long lifespan, and they replicate rarely, 
though they have the self-duplication ability [16, 72]. 
However, this self-duplication cannot counterbalance 
the excessive loss of b-cells and for compensating 
the excessive loss of b-cells, mature glucagon secreting 
a-cells have been traced to differentiate to b-cells 
[85]. This kind of cellular transition is possible becau- 
se a- and b-cells are formed from the same multipo-
tent progenitors during pancreatic islet development 
[70, 86].
Lineage tracing in diphtheria-toxin induced total 
b-cell ablation mouse model showed that a-cells were 
the source of b-cell regeneration [83]. In another 
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in vivo model of b-cell regeneration, Chung et al. 
used partial duct ligation and alloxan for ablation 
of existing b-cells [85]. After two weeks it was found 
that neogenic b-cells came from a-cells. The authors 
documented that in this model a-cells were not di-
rectly converted to b-cells, but instead, they passed 
through an intermediate stage in which they express 
the markers for both a-and b-cells and secrete both 
glucagon and insulin after one week of b-cell ablation 
[85]. However, after two weeks of PDL plus alloxan 
combination, the glucagon secretion was minute, and 
the cells resembled b-cells in phenotype and the ex-
pression of MafA was also high [85]. In another study, 
zebrafish was used as a model for lineage tracing of 
b-cell regeneration using near total ablation of existing 
b-cells [84]. The expression of glucagon was increased 
after the injury suggesting its role in a- to b-cell trans-
differentiation. These results, in favor of previous 
studies, showed that a-cells serve as a reservoir pool 
for the b-cell regeneration [84] and imply the plasticity 
of the a-cells to be converted into b-cells [70].
Andrzejewski et al. reported the role of activin 
signaling in a-to b-cell phenotype transition. They 
treated a-and b-cell lines and also sorted mouse islet 
cells with activin [24]. In aTC1-6 a-cell line, the ex-
pression of a-cell genes, Aristaless-related homeobox 
(Arx), glucagon, and MafB was suppressed following 
the treatment with activin A or B. In INS-1E b-cell 
line, the expression of Pax4 and insulin was increased 
following the activin A treatment [24]. Furthermore, 
the exposure to activin A suppressed the expression 
of a-cell genes and enhanced the expression of b-cell 
genes in sorted primary islet cells. These results 
suggest that activin signaling destabilized the a-cell 
phenotype whereas promoted a b-cell fate in cultured 
cells [24]. To further verify the hypothesis of activin 
mediated a- to b-cell transdifferentiation, Brown et al. 
developed Fstl3 knockout mouse labeled with Gluc-
Cre/yellow fluorescent protein (YFP) for lineage 
tracing [87]. Follistatin-like 3 (Fstl3) is the antagonist 
of activin, and its inactivation resulted in the expan-
sion of b-cell mass and improved glucose homeostasis 
[88]. The number of Ins+/YFP+ cells was significantly 
increased in Fstl3 KO mice compared with wild type 
mice. The treatment of isolated islets with activin 
resulted in a significantly increased number of YFP+/ 
/Ins+ cells [87]. These pieces of evidence suggested 
that transdifferentiation of a-cells to b-cells was 
influenced by activin signaling and contributed sub-
stantially to b-cell mass [87].
Chakravarthy et al. deciphered another possible 
mechanism for the conversion of a-cells to b-cells in 
adult mice [89]. The inactivation of two regulators of 
a-cell functionality, Arx and DNA methyltransferase 1 
(Dnmt1), resulted in the conversion of a-cells to 
b-cells. This conversion took three months, and the 
newly formed b-cells were similar to native b-cells 
when checked for gene expression using RNA-se-
quence. The neogenic b-cells also secreted insulin 
upon glucose stimulation [89]. In 2017, two remark-
able reports showed the role of gamma-aminobutyric 
acid (GABA), a neurotransmitter found in the nerv-
ous system and also in the endocrine pancreas [90], 
in a-to b-cell transition [91, 92]. In the first report 
Ben-Othman et al. reported that GABA induces the 
a-cell-mediated b-cell neogenesis in vivo in mice after 
three months of treatment with GABA. The newly 
produced b-cells were functional and could replace 
the native b-cells. When newly transplanted human 
islets were treated with GABA, they showed an in-
creased number of b-cells at the cost of a-cells [91]. 
In a similar report, Li et al. [92] tested artemisinin, 
an antimalarial drug which enhances GABA signaling 
by binding to GABAA receptors, for b-cell neogenesis 
from a-cells. Artemisinin repressed the master regu-
lator of glucagon-secreting a-cells, Arx, by causing its 
displacement to the cytoplasm. Thus, the a-cells lost 
their identity and were transdifferentiated to b-cells in 
zebrafish, rodents and primary human pancreatic is-
lets [92]. However, a recent study by Ackermann et al. 
contradicted the role of both GABA and antimalarial 
drug in the a- to b-cells conversion [93]. They treated 
mice for three months with artesunate and GABA 
and showed by cell-specific genetic lineage tracing 
that no a- to b-cells transdifferentiation happened 
and insulin secretion was also not stimulated [93]. In 
another recent report, Shin et al. used rhesus monkey 
to translate the rodent b-cell regeneration model [94]. 
They used STZ for b-cell ablation followed by porcine 
islet transplantation to maintain normoglycemia, but 
in both conditions, there was no increase in b-cell 
number or serum C-peptide level. They also checked 
the in vivo and in vitro transdifferentiation ability of a- 
to b-cells by GABA treatment, and yet again no b-cell 
regeneration was found [94]. Eizirik and Gurzov [95] 
proposed four main reasons for the contrary results 
of the reported papers [91–94] and first of them was 
the use of different experimental models: zebrafish, 
rodents and primary human pancreatic islands [92], 
a single mice model [93], mice model that was con-
firmed in human and rat [91], rhesus monkey [94]. 
Secondly, Ackerman et al. used tamoxifen-induced 
lineage-tracing for following the adult a- to b-cell 
transition [93] whereas Ben-Othman et al. used 
Glucagon-Cre mice which can also detect the b-cell 
neogenesis from a transient and putative cell state 
expressing glucagon [91]. Thirdly, the GABA used 
in those experiments was not made for purpose of in 
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vivo use and finally, the diet and housing conditions 
were different in those laboratories which could have 
affected the murine microbiome and ultimately drug 
metabolism and systemic mouse metabolism [95].
Thus, we come to know that under the severe loss 
of b-cells due to metabolic stress or injury, the tran-
sition of a-cells to b-cells becomes stimulated. The 
regulation of this conversion is possible due to the 
genetic programming which involves the repression of 
a-cell genes and activation of b-cell genes. Therefore, 
different factors which can repress the a-cell signature 
genes and/or enhance the b-cell signature genes in 
a-cells can be used for designing a fruitful protocol 
for in vitro generation of b-like cells from a-cells.
d-cells transdifferentiation to b-cells
Delta cells are found in the islets of Langerhans and 
they are responsible for somatostatin secretion [96]. 
The attempts to find the source of new b-cells and lo-
cation of dedicated or facultative progenitors in adult 
mammals led to the studies for d- to b-cell transdiffer-
entiation following the models of a- to b-cell transdif-
ferentiation [97]. Chera et al. administered diphtheria 
toxin (DT) to postnatal two week-old mice and adult 
mice for ablation of b-cells [25]. The administration 
of DT resulted in 99% ablation of b-cells; however, 
afterwards mice regenerated b-cells from other islet 
cells. The lineage tracing revealed that in the adult 
mice the induction of post-DT b-cell regeneration was 
by transdifferentiation of a-cells while in mouse pups 
the d-cells were dedifferentiated and reprogrammed 
to b-cells. The dedifferentiated cells showed fewer 
somatostatin transcripts, and high insulin transcripts 
and no polyhormonal cells were found [25]. Druelle et 
al. generated and characterized Cre-LoxP transgenic 
mice that express Pax4 specifically in somatostatin-ex-
pressing d-cells cells [97]. They demonstrated that 
the ectopic expression of Pax4 in d cells is sufficient 
to induce their conversion into functional b-like cells 
that can partly reverse chemically-induced diabetes 
and induce b-like cell hyperplasia [97].
Although more work is needed for validation of 
d-cells as the source of in vivo b-cell expansion, these 
results favor the plasticity of islet cells for their trans-
differentiation into b-cells.
The summary of some factors used for the differ-
entiation of pancreatic endocrine cells to b-like cells 
is presented in Figure 2.
Pancreatic islet-derived mesenchymal stem 
cells giving rise to b-like cells
Mesenchymal stem cells (MSCs) can differentiate into 
many target cells depending upon the applied condi-
tions [98–100]. It was shown that transplantation of 
bone marrow-derived [101] and adipose tissue-derived 
[102] MSCs enhanced the regeneration of pancreatic 
islet and decreased the blood glucose levels of dia-
betic animals [103]. Furthermore, MSCs have shown 
a decent safety profile in clinical trials with limited 
risk of tumor formation [104]. The pancreatic islet 
also has mesenchymal stem cells (PI-MSCs) which 
play important roles as a source of ECM and during 
pancreatic islet injury. Here, we will shortly report 
studies showing the use of these PI-MSCs as a source 
of insulin-producing cells.
The quest for finding the stem or progenitor cells 
in the pancreas has led the researchers to search for 
these cells in different compartments of the pancreas. 
Zulewski et al. showed that rat and human pancreatic 
islets contain the distinct population of cells positive 
for neural stem-cell-specific marker nestin [105]. 
Apart from the islets of Langerhans, pancreatic 
ducts also contain the nestin-positive cells with the 
capability of giving rise to b-cells as we have discussed 
earlier. In in vitro culture, the nestin-positive cells have 
shown boundless proliferation and differentiation 
abilities as these cells were differentiated to acinar, 
ductal, and endocrine phenotype cells [105]. These 
findings suggested that the pancreatic islets have the 
progenitor cells with the ability to regenerate the is-
lets of Langerhans [105]. Karaoz et al. isolated stem 
cells (SCs) from pancreatic islets and characterized 
their stem cell properties [106]. They found that the 
pancreatic islets SCs expressed the markers of embry-
onic SCs (Oct-4, Sox-2, and Rex-1) and also showed 
the high proliferation ability coinciding with the 
Figure 2. Some factors used for in vitro b-cell replication (A) 
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bone marrow MSCs. Furthermore, these pancreatic 
islets SCs expressed the differentiation markers of 
adipo-, chondro-, neuro-, myo-, and osteogenic cells 
[106]. Thus, pancreatic islets contain stem cell with 
the ability to be expanded in vivo for replacement 
therapy of diabetes [106]. Gong et al. found that 
the CD117-positive cells were very few in normal 
pancreatic tissue, but their number increased after 
induction of pancreatitis [107]. In this model of pan-
creatic inflammation, the CD117-positive cells were 
only present in the pancreatic islet and participated 
only in the repair of islets of Langerhans but not in 
the repair of extra-islet pancreatic tissue. Thus, these 
findings suggested that the CD117 positive progenitor 
cells are not the true stem cells, but merely a type of 
islet progenitor or precursor cells [107].
It has been shown that microenvironment is im-
portant for the regulation of stem cells proliferation 
and differentiation [26]. Use of glycated collagen 
in culture media resulted in the induction of rat 
pancreatic islet-derived mesenchymal stem cells 
differentiation to insulin-secreting cells. PI-MSCs 
were induced by using glucose, hEGF, nicotinamide, 
activin-A, exendin-4, hHGF, and pentagastrin [26]. 
The differentiation efficiency and insulin expression 
in collagen cultures were higher than in control cul-
tures; however, glucagon was also present in media 
showing the presence of a-cells [26]. Coskun et al. 
showed that valproic acid, class-I histone deacetylase 
inhibitor (HDACi) and glucose induced the differ-
entiation of PI-MSCs to insulin-secreting cells with 
a fair efficiency, however, the newly formed b-cells 
were non-functional [108].
Gao et al. were the first to culture bovine pan-
creatic MSCs of (B-PMSCs) for differentiation to 
insulin-producing cells [109]. Growth kinetics of 
B-PMSCs revealed their decent in vitro self-renewal 
capability. Retinoic acid, HGF, and EGF were used 
for the induction of stem cells to insulin-secreting 
clusters. After 21 days of culture, the DTZ staining 
showed the presence of b-cells which were positive for 
glucose-stimulated insulin-secretion in culture media 
[109]. Most recently, the differentiation of MSCs from 
different sources into IPCs within 3D alginate matri-
ces was performed by Cañibano-Hernández et al. [5]. 
MSCs from different sources were used, but the quan-
tity of insulin released was high in IPCs differentiated 
from pancreatic islet-derived MSCs. Moreover, the 
amount of insulin secreted was increased after adding 
hyaluronic acid (HA) in alginate microcapsules [5].
The b-like cells developed in vitro in the presence 
of cytokines and/or inhibitors mentioned above were 
less in number and also were not functional enough 
to serve as the b-cell replacement source. In order 
to achieve the maturation of in vitro produced b-like 
cells, Nair et al. elegantly reported a reliable method 
for the maturation of in vitro generated b-like cells 
[110]. They recapitulated the culture conditions mim-
icking in vivo pancreatic islet organogenesis and b-cell 
maturation. In these conditions, the immature b-like 
cells were isolated and reaggregated in the form of 
islet-size enriched b-cell clusters (eBCs) — each eBCs 
comprised by aggregation of 1000 b-like cells mimick-
ing the number of cells present in human islet [110]. 
After seven days, eBCs showed the properties of ma-
ture b-cells. The physiological properties exhibited by 
eBCs presented dynamic insulin secretion, increased 
calcium signaling in response to secretagogues, 
and improved mitochondrial energetics resembling 
primary human b-cells. Unlike previous studies in 
which long time was required for insulin secretion 
[28, 111], within three days of transplantation in mice, 
eBCs showed glucose-stimulated insulin secretion 
[110]. However, some dual-hormone cells, the likely 
progenitors of glucagon-secreting a-cells were also 
present in the clusters produced.
Conclusions
Attempts to control the diabetic epidemic have 
resulted in the development of many strategies for 
the replacement of b-cells. Still, to the best of our 
knowledge, in vitro development of functional islets 
or insulin-producing cells is not efficient enough to be 
used as a routine clinical option for curing diabetes due 
to many problems. These problems include production 
in low number, immature b-cell production, secretion 
of low amount of insulin, polyhormonal nature of cells, 
the impurity of cells, and the high cost of factors used 
in protocols for in vitro differentiation. While devel-
oping in vitro protocol, tactics like the recapitulation 
of in vivo conditions can warrant the production of an 
ample number of mature and functional b-cells. How-
ever, for mirroring in vivo conditions, first, we need to 
have vibrant knowledge about pancreas development 
which is instead a convoluted process and not fully 
understood yet. Though, the use of three-dimensional 
culture systems and tools like single-cell transcrip-
tome analysis can help us understand the cellular and 
molecular mechanisms of pancreatic development 
assisting in the development of viable protocols for in 
vitro production of bona fide b-like cells.
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